|
Gene: TFG |
Gene summary for TFG |
Gene summary. |
Gene information | Species | Human | Gene symbol | TFG | Gene ID | 10342 |
Gene name | trafficking from ER to golgi regulator | |
Gene Alias | HMSNP | |
Cytomap | 3q12.2 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q92734 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10342 | TFG | A015-C-006 | Human | Colorectum | FAP | 1.08e-12 | -4.72e-01 | -0.0994 |
10342 | TFG | A015-C-106 | Human | Colorectum | FAP | 8.88e-16 | -3.94e-01 | -0.0511 |
10342 | TFG | A002-C-114 | Human | Colorectum | FAP | 6.62e-14 | -4.38e-01 | -0.1561 |
10342 | TFG | A015-C-104 | Human | Colorectum | FAP | 8.41e-24 | -4.65e-01 | -0.1899 |
10342 | TFG | A001-C-014 | Human | Colorectum | FAP | 2.05e-15 | -4.29e-01 | 0.0135 |
10342 | TFG | A002-C-016 | Human | Colorectum | FAP | 1.75e-22 | -4.28e-01 | 0.0521 |
10342 | TFG | A015-C-002 | Human | Colorectum | FAP | 4.40e-10 | -5.01e-01 | -0.0763 |
10342 | TFG | A001-C-203 | Human | Colorectum | FAP | 2.82e-11 | -4.16e-01 | -0.0481 |
10342 | TFG | A002-C-116 | Human | Colorectum | FAP | 1.24e-25 | -4.82e-01 | -0.0452 |
10342 | TFG | A014-C-008 | Human | Colorectum | FAP | 2.45e-09 | -4.13e-01 | -0.191 |
10342 | TFG | A018-E-020 | Human | Colorectum | FAP | 1.17e-16 | -5.12e-01 | -0.2034 |
10342 | TFG | F034 | Human | Colorectum | FAP | 2.78e-21 | -4.89e-01 | -0.0665 |
10342 | TFG | F072B | Human | Colorectum | FAP | 8.37e-06 | -2.32e-01 | 0.257 |
10342 | TFG | CRC-1-8810 | Human | Colorectum | CRC | 2.49e-05 | -2.54e-01 | 0.6257 |
10342 | TFG | CRC-3-11773 | Human | Colorectum | CRC | 2.72e-05 | -2.05e-01 | 0.2564 |
10342 | TFG | AEH-subject1 | Human | Endometrium | AEH | 6.30e-07 | -5.78e-02 | -0.3059 |
10342 | TFG | AEH-subject2 | Human | Endometrium | AEH | 8.04e-06 | -9.96e-02 | -0.2525 |
10342 | TFG | AEH-subject3 | Human | Endometrium | AEH | 3.43e-05 | -6.52e-02 | -0.2576 |
10342 | TFG | AEH-subject4 | Human | Endometrium | AEH | 2.76e-05 | -2.05e-01 | -0.2657 |
10342 | TFG | EEC-subject1 | Human | Endometrium | EEC | 3.42e-08 | -1.55e-01 | -0.2682 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
GO:00092678 | Cervix | CC | cellular response to starvation | 39/2311 | 156/18723 | 1.04e-05 | 2.32e-04 | 39 |
GO:00425948 | Cervix | CC | response to starvation | 46/2311 | 197/18723 | 1.24e-05 | 2.59e-04 | 46 |
GO:00316698 | Cervix | CC | cellular response to nutrient levels | 49/2311 | 215/18723 | 1.32e-05 | 2.68e-04 | 49 |
GO:000690010 | Cervix | CC | vesicle budding from membrane | 20/2311 | 61/18723 | 2.50e-05 | 4.28e-04 | 20 |
GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
GO:19031314 | Cervix | CC | mononuclear cell differentiation | 76/2311 | 426/18723 | 5.66e-04 | 5.42e-03 | 76 |
GO:00431237 | Cervix | CC | positive regulation of I-kappaB kinase/NF-kappaB signaling | 37/2311 | 186/18723 | 2.15e-03 | 1.55e-02 | 37 |
GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
GO:0002263 | Cervix | CC | cell activation involved in immune response | 50/2311 | 279/18723 | 4.16e-03 | 2.57e-02 | 50 |
GO:00300981 | Cervix | CC | lymphocyte differentiation | 63/2311 | 374/18723 | 6.21e-03 | 3.52e-02 | 63 |
GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
GO:0006900 | Colorectum | AD | vesicle budding from membrane | 32/3918 | 61/18723 | 5.38e-08 | 2.81e-06 | 32 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa052161 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa052164 | Colorectum | FAP | Thyroid cancer | 12/1404 | 37/8465 | 1.33e-02 | 4.46e-02 | 2.71e-02 | 12 |
hsa052165 | Colorectum | FAP | Thyroid cancer | 12/1404 | 37/8465 | 1.33e-02 | 4.46e-02 | 2.71e-02 | 12 |
hsa0521610 | Endometrium | AEH | Thyroid cancer | 12/1197 | 37/8465 | 3.68e-03 | 2.14e-02 | 1.56e-02 | 12 |
hsa0521615 | Endometrium | AEH | Thyroid cancer | 12/1197 | 37/8465 | 3.68e-03 | 2.14e-02 | 1.56e-02 | 12 |
hsa0521625 | Endometrium | EEC | Thyroid cancer | 13/1237 | 37/8465 | 1.51e-03 | 9.55e-03 | 7.12e-03 | 13 |
hsa0521635 | Endometrium | EEC | Thyroid cancer | 13/1237 | 37/8465 | 1.51e-03 | 9.55e-03 | 7.12e-03 | 13 |
hsa0521620 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa05216110 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa0521628 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa0521638 | Esophagus | ESCC | Thyroid cancer | 32/4205 | 37/8465 | 2.98e-06 | 1.72e-05 | 8.81e-06 | 32 |
hsa052167 | Liver | Cirrhotic | Thyroid cancer | 23/2530 | 37/8465 | 4.63e-05 | 3.28e-04 | 2.02e-04 | 23 |
hsa0521612 | Liver | Cirrhotic | Thyroid cancer | 23/2530 | 37/8465 | 4.63e-05 | 3.28e-04 | 2.02e-04 | 23 |
hsa0521622 | Liver | HCC | Thyroid cancer | 29/4020 | 37/8465 | 1.18e-04 | 5.88e-04 | 3.27e-04 | 29 |
hsa0521632 | Liver | HCC | Thyroid cancer | 29/4020 | 37/8465 | 1.18e-04 | 5.88e-04 | 3.27e-04 | 29 |
hsa0521618 | Oral cavity | OSCC | Thyroid cancer | 27/3704 | 37/8465 | 2.97e-04 | 9.39e-04 | 4.78e-04 | 27 |
hsa0521619 | Oral cavity | OSCC | Thyroid cancer | 27/3704 | 37/8465 | 2.97e-04 | 9.39e-04 | 4.78e-04 | 27 |
hsa0521627 | Oral cavity | LP | Thyroid cancer | 21/2418 | 37/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 21 |
hsa0521637 | Oral cavity | LP | Thyroid cancer | 21/2418 | 37/8465 | 2.98e-04 | 1.60e-03 | 1.03e-03 | 21 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TFG | SNV | Missense_Mutation | c.455C>T | p.Ser152Phe | p.S152F | Q92734 | protein_coding | tolerated(0.07) | benign(0.1) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD | |
TFG | SNV | Missense_Mutation | novel | c.513A>T | p.Leu171Phe | p.L171F | Q92734 | protein_coding | tolerated(0.05) | probably_damaging(0.991) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
TFG | SNV | Missense_Mutation | c.1165N>T | p.Gly389Cys | p.G389C | Q92734 | protein_coding | tolerated_low_confidence(0.08) | benign(0.334) | TCGA-E9-A1R2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR | |
TFG | SNV | Missense_Mutation | novel | c.658C>T | p.Pro220Ser | p.P220S | Q92734 | protein_coding | tolerated(0.08) | benign(0.057) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
TFG | SNV | Missense_Mutation | c.455N>T | p.Ser152Phe | p.S152F | Q92734 | protein_coding | tolerated(0.07) | benign(0.1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TFG | SNV | Missense_Mutation | rs146078119 | c.1147N>T | p.Arg383Cys | p.R383C | Q92734 | protein_coding | tolerated_low_confidence(0.05) | benign(0.005) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TFG | SNV | Missense_Mutation | novel | c.519N>A | p.Asn173Lys | p.N173K | Q92734 | protein_coding | tolerated(0.06) | probably_damaging(0.979) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TFG | SNV | Missense_Mutation | novel | c.519C>A | p.Asn173Lys | p.N173K | Q92734 | protein_coding | tolerated(0.06) | probably_damaging(0.979) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TFG | SNV | Missense_Mutation | rs373719892 | c.1154G>A | p.Arg385His | p.R385H | Q92734 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.987) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TFG | SNV | Missense_Mutation | rs774808090 | c.68N>A | p.Arg23Gln | p.R23Q | Q92734 | protein_coding | deleterious(0) | possibly_damaging(0.552) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |